Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Internal Medicine"
DOI: 10.1111/joim.12633
Abstract: With the introduction of next‐generation sequencing, the genetic landscape of the complex group of B‐cell lymphoid malignancies has rapidly been unravelled in recent years. This has provided important information about recurrent genetic events and identified… read more here.
Keywords: medicine; lymphoid malignancies; cell lymphoid; genetic landscape ... See more keywords
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies
Sign Up to like & getrecommendations! Published in 2024 at "Cancers"
DOI: 10.3390/cancers16203434
Abstract: Simple Summary Bruton’s tyrosine kinase inhibitors (BTKi) have revolutionized the treatment of various B-cell lymphoid malignancies. However, acquisition of resistance to BTKi has emerged as an important clinical challenge. Herein, we provide a detailed review,… read more here.
Keywords: resistance; cell lymphoid; btk; lymphoid malignancies ... See more keywords
SARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment
Sign Up to like & getrecommendations! Published in 2024 at "Vaccines"
DOI: 10.3390/vaccines12090961
Abstract: Background: Patients with B-lymphocyte malignancies (BCMs) receiving B-lymphocyte-targeted therapies have increased risk of severe COVID-19 outcomes and impaired antibody response to SARS-CoV-2 mRNA vaccination in comparison to non-hematologic oncologic patients or general population. Consequently, it… read more here.
Keywords: sars cov; treatment; analysis; response ... See more keywords